Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Summary

This study enrolled participants with previously-treated advanced or inoperable gastric cancer who have responded to first line platinum therapy into two treatment arms. In Arm A participants received BGB-290; in Arm B participants received placebo. The purpose of this study is to show that BGB-290 (pamiparib) (versus placebo) will improve progression-free survival (PFS) in participants with advanced or inoperable gastric cancer.

Timeline

Start

2018-07-03

Primary completion

2020-06-18

Completion

2023-01-03

Drugs

Indications